YORK, Nov. 24, 2022 /PRNewswire/ -- The Global
Neurological Biomarkers Market size is expected to reach
$12.9 billion by 2028, rising at a
market growth of 14.2% CAGR during the forecast period.
Read the full report:
The term "biomarker," a portmanteau of "biological marker," refers
to a large subclass of medical signs, or objective indicators of
health status seen from the outside of the patient, which can be
quantified precisely and consistently. Medical symptoms, on the
other hand, are only those markers of health or disease that
patients themselves may perceive. The literature contains several
more detailed definitions of biomarkers, and they have a lot in
A biomarker is "a characteristic that is measured and evaluated
objectively as an indicator of normal biochemical functions,
pathogenic processes, or pharmacologic responses to a therapeutic
intervention," according to the National Institutes of Health
Biomarkers Definitions Working Group definition from 1998.
The World Health Organization (WHO), in collaboration with the
United Nations and the International Labor Organization,
established the International Program on Chemical Safety, which
defines a biomarker as "any substance, structure, or procedure that
can be evaluated in the body or its product lines and influence or
predict the incidence of outcome or disease.
A definition that goes even further considers not only the
occurrence and course of a disease, but also its treatment,
interventions, and even inadvertent environmental exposure to
substances like toxins or nutrients. Before the invention of better
technology, it was difficult for researchers to monitor brain
health by analyzing molecules since there were so few biomarkers
for neurological illnesses. This entails less invasive testing,
quicker medication development, earlier diagnosis, and hopefully
more efficient therapies.
COVID-19 Impact Analysis
Almost every business has been impacted by the unmatched worldwide
public health emergency known as COVID-19, and the long-term
impacts are expected to influence industry growth throughout the
course of the forecast period. According to research by Diaceutics
PLC (UK) on the diagnosis and biomarker testing rates for various
cancer types, the number of newly diagnosed patients with
metastatic non-small cell lung cancer decreased between
February 2020 and March 2020. The rates of KRAS, BRAF, and EGFR
testing, which are important indicators supporting the optimal
choice of precision medicine medicines that benefit particular
patients, were also significantly influenced by this abrupt decline
in just one month.
Market Growth Factor
Companion Diagnostics Are Becoming More Important
In the practice of medicine, companion diagnostics and biomarkers
are becoming more and more important, which has enhanced
disease-specific diagnosis, therapy, and monitoring. It can be used
to identify patients who will likely respond well to specific
treatments or drugs. These diagnostics frequently go hand in hand
with certain medicine.
The Growing Concept of Individual Medicine
In customized medicine, biomarkers are crucial because they can be
used for diagnosis, prognosis, and choosing specific treatments.
Personalized medicine has grown in popularity over time as a result
of the different drawbacks of conventional methods for diagnosis
and treatment. Numerous medical specialties from cancer to
immunological disorders are moving toward individualized patient
care based on their genetic profiles and phenotypic traits.
Market Restraining Factor
High Startup Costs and Protracted Biomarker Development Cycles
Due to the variability in how well they perform in illness
detection, evaluating biomarkers is a time-consuming process. As a
result, the validation procedure grows expensive and
time-consuming. The process and timetable for developing and
validating biomarkers are therefore comparable across biomarker
categories, with a few exceptions, because different categories of
biomarkers frequently share common development and validation
Based on the Type, the Neurological Biomarkers Market is segmented
into Genomic, Proteomic, Metabolomic, and Others. The genomic
segment acquired a significant revenue share in the neurological
biomarkers market in 2021. Increased prevalence of neurological
disorders, an increase in the estimated incidence of ischemic
stroke, elevated demand for minimally procedures, technological
advancements in clinical laboratory tests and rising public
awareness of genomic biomarker-based personalized medicines are all
contributing factors to the expansion of the genomic biomarkers
On the basis of Application, the Neurological Biomarkers Market is
divided into Parkinsonâ€™s Disease, Alzheimerâ€™s Disease, and
Multiple Sclerosis. The Alzheimerâ€™s disease segment procured the
largest revenue share in the neurological biomarkers market in
2021. due to an increase in clinical trials, research, and drug
development as well as an increase in the prevalence of
Alzheimerâ€™s disease. Drug development for Alzheimerâ€™s disease
(AD) heavily relies on biomarkers.
Region-wise, the Neurological Biomarkers Market is analyzed across
North America, Europe, Asia
Pacific, and LAMEA. The North
America segment garnered the highest revenue share in the
neurological biomarkers market in 2021. The increase in American
studies suggests a decrease in the age-specific risk of
Alzheimerâ€™s disease and other forms of dementia in the United States and other high-income
western nations over the previous 25 years.
The market research report covers the analysis of key stake holders
of the market. Key companies profiled in the report include F.
HOFFMANN-LA ROCHE LTD., Bio-Rad Laboratories, Inc., Merck Group,
PERKINELMER INC., Shimadzu corporation, Thermo Fisher Scientific,
Inc., Quanterix Corporation, Neuro-Bio Ltd., BioMÃ©rieux S.A. and
Myriad Genetics, Inc.
Scope of the Study
Market Segments covered in the Report:
â€¢ Alzheimerâ€™s Disease
â€¢ Parkinsonâ€™s Disease
â€¢ Multiple Sclerosis
â€¢ North America
o Rest of North America
o Rest of Europe
â€¢ Asia Pacific
o South Korea
o Rest of Asia Pacific
o Saudi Arabia
o South Africa
o Rest of LAMEA
â€¢ F. HOFFMANN-LA ROCHE LTD.
â€¢ Bio-Rad Laboratories, Inc.
â€¢ Merck Group
â€¢ PERKINELMER INC.
â€¢ Shimadzu corporation
â€¢ Thermo Fisher Scientific, Inc.
â€¢ Quanterix Corporation
â€¢ Neuro-Bio Ltd.
â€¢ BioMÃ©rieux S.A.
â€¢ Myriad Genetics, Inc.
â€¢ Exhaustive coverage
â€¢ Highest number of market tables and figures
â€¢ Subscription based model available
â€¢ Guaranteed best price
â€¢ Assured post sales research support with 10% customization
Read the full report:
ReportLinker is an award-winning market research solution.
Reportlinker finds and organizes the latest industry data so you
get all the market research you need - instantly, in one place.
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001